Literature DB >> 33080231

AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review.

Michael Dougan1, Yinghong Wang2, Alberto Rubio-Tapia3, Joseph K Lim4.   

Abstract

BACKGROUND & AIMS: Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for oncology, leading to durable remissions in a subset of patients, but also a broad range of potentially life-threatening inflammatory toxicities, many of which involve the gastrointestinal (GI) tract and liver. The purpose of this expert review was to update gastroenterologists on the gastrointestinal and hepatic toxicities of ICIs and provide best practice advice on their diagnosis and management.
METHODS: The evidence reviewed in this work combines the expert clinical opinion of the authors with a comprehensive search of several English-language databases and a manual review of relevant publications.
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adverse Event; Enterocolitis; Hepatitis; Immune Checkpoint Inhibitor; Toxicity

Mesh:

Substances:

Year:  2020        PMID: 33080231     DOI: 10.1053/j.gastro.2020.08.063

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  25 in total

1.  Gas Bubbles: A Persistent Problem with Immunotherapy.

Authors:  Barnabas Yik; Nimeesh Shah
Journal:  Dig Dis Sci       Date:  2021-01-06       Impact factor: 3.199

2.  Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab.

Authors:  Grazia Graziani; Lucia Lisi; Lucio Tentori; Pierluigi Navarra
Journal:  Exp Suppl       Date:  2022

3.  Checking Out the Associations Between Inflammatory Bowel Disease and Checkpoint Inhibitor Colitis.

Authors:  Tenzin Choden; Mia Yeager; Russell D Cohen
Journal:  Dig Dis Sci       Date:  2022-09-13       Impact factor: 3.487

4.  Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects.

Authors:  Cynthia Liu; Rajan Amin; Anusha S Thomas; Yinghong Wang; Malek Shatila; Nicholas Short; Mehmet Altan; Amishi Shah; Omar Alhalabi; Pablo Okhuysen
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-28       Impact factor: 4.322

5.  Severe immune checkpoint inhibitor-associated gastritis: A case series and literature review.

Authors:  Yuya Sugiyama; Hiroki Tanabe; Taisuke Matsuya; Yu Kobayashi; Yuki Murakami; Takahiro Sasaki; Takehito Kunogi; Keitaro Takahashi; Katsuyoshi Ando; Nobuhiro Ueno; Shin Kashima; Kentaro Moriichi; Mishie Tanino; Yusuke Mizukami; Mikihiro Fujiya; Toshikatsu Okumura
Journal:  Endosc Int Open       Date:  2022-07-15

6.  Case Report: Fulminant Celiac Disease With Combination Immune Checkpoint Therapy.

Authors:  Ayo S Falade; Kerry L Reynolds; Leyre Zubiri; Vikram Deshpande; Florian J Fintelmann; Michael Dougan; Meghan J Mooradian
Journal:  Front Immunol       Date:  2022-04-14       Impact factor: 8.786

7.  Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients.

Authors:  Bart van Hoek; Ellen Kapiteijn; Maaike Biewenga; Monique K van der Kooij; Michel W J M Wouters; Maureen J B Aarts; Franchette W P J van den Berkmortel; Jan Willem B de Groot; Marye J Boers-Sonderen; Geke A P Hospers; Djura Piersma; Rozemarijn S van Rijn; Karijn P M Suijkerbuijk; Albert J Ten Tije; Astrid A M van der Veldt; Gerard Vreugdenhil; John B A G Haanen; Alfons J M van der Eertwegh
Journal:  Hepatol Int       Date:  2021-02-25       Impact factor: 6.047

8.  Use of Vedolizumab in Immune Checkpoint Inhibitor-associated Enterocolitis.

Authors:  Molly L Stone; Erin M Forster
Journal:  Inflamm Bowel Dis       Date:  2021-11-15       Impact factor: 7.290

Review 9.  Understanding and treating the inflammatory adverse events of cancer immunotherapy.

Authors:  Michael Dougan; Adrienne M Luoma; Stephanie K Dougan; Kai W Wucherpfennig
Journal:  Cell       Date:  2021-03-05       Impact factor: 41.582

10.  Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study.

Authors:  Joseph Sleiman; Wei Wei; Ravi Shah; Muhammad Salman Faisal; Jessica Philpott; Pauline Funchain
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.